Archive for July, 2010

Pharmaceutical Industry and Psychiatry—Conjoined Twins Joined at the Wallet, by former Pharma rep turned whistleblower

Friday, July 30th, 2010

OpEdNews
By K. L. Carlson
July 30, 2010

“Unlimited spending! Schedule all the programs you can.” That was the management directive announced at the regional business meeting I attended when I first became a pharmaceutical rep. When I heard the announcement I felt like I was on an Enron train that was roaring down the tracks, and the company expected everyone to be on board. The company was giving its sales force unlimited funds to hire physicians as paid speakers, sometimes to influence other physicians to prescribe the company’s drugs, at other times to simply financially reward physicians who wrote high volumes of prescriptions every month for the company’s drugs.

Former Merck regional sales manager, Gene Carbona, told the New York Times that the only thing the company considered when selecting physicians to provide presentations was “the volume or potential volume of prescribing that the doctor could do.” This is true of all pharmaceutical companies. According to The Wall Street Journal (August 31, 2009), Eli Lilly alone paid physicians $22 million dollars in just the first quarter of 2009.

The higher a physician is on the influential ladder, the greater the financial rewards to be reaped. Pharmaceutical companies pay influential leaders who can sway public opinion and influence research. And the area of medicine receiving the greatest amount of pharmaceutical money is psychiatry. The American Psychiatric Association (APA) is the most drug industry financially supported medical association. In July 2008, Senator Charles Grassley’s demands that the APA provide an accounting of its finances revealed that in 2006 the pharmaceutical industry accounted for about 30 percent of the APA’s financing; more than $20 million dollars.

Read entire article here:  http://www.opednews.com/articles/Pharmaceutical-Industry-an-by-K-L-Carlson-100727-454.html

« Return to news items


Share

Austrailan Psychiatrist Patrick McGorry’s Global Agenda for “Pre-Psychosis Risk Syndrome” Takes A Hit from Former DSM Task Force Member, Psychiatrist Allen Frances

Friday, July 30th, 2010

Note: The diagnosis being pushed for global implementation, “Pre-Psychosis Risk Syndrome” by “Australian of the Year,” Psychiatrist Patrick McGorry, takes a hit from a worthy opponent, Psychiatrist Allen Frances, former Chairiman of the DSM Task force. For more information about Patrick McGorry’s global agenda, click here:http://www.cchrint.org/2010/06/16/australian-psychiatrist-patrick-mcgorry-wants-his-pre-drugging-agenda-to-go-global/

DSM5 in Distress
Psychology Today
by Allen Frances, MD

The DSM 5 Workgroup that first suggested the inclusion of “Psychosis Risk Syndrome” has halfway come to its senses. It has dropped this stigmatizing name in a last ditch repackaging effort to salvage the proposal. The criteria set remains essentially the same, but is relabeled with the equally awkward title: “Attenuated Psychotic Symptoms Syndrome”. The suggestion remains just as dangerous and stigmatizing, whatever it is called.

Why the halfway reversal by the Workgroup at this late date? The “Psychosis Risk” proposal has stimulated widespread opposition (even I am told from within the Workgroup itself). The arguments against it are simply overwhelming. The false positive rate in predicting psychosis would be between 70-90%, meaning that between two and nine youngsters would be misidentified for every one accurately identified. The treatment most likely to be used would be antipsychotic medications. These have no proven efficacy in preventing psychosis, but most definitely have terrible side effects- especially enormous weight gain and its life threatening complications. These medications are overprescribed to those least able to resist- the young and those who are most financially disadvantaged.

Finally, the name “Psychosis Risk” was filled with ominous threat and stigma. Having a label that suggests one is at risk to soon develop a psychosis would cause the mislabelled person much unnecessary worry, unnecessarily reduced ambitions, and create great risk of discrimination in getting work or insurance – thus further exacerbating the risk side of the already totally unbalanced risk-benefit ratio.

As an early intervention strategy, everything that could possibly be wrong was wrong with “Psychosis Risk Syndrome”. An extremely inaccurate diagnosis would lead to widespread treatment with an ineffective but dangerous medication. To top it off, the writing of the criteria set is remarkably vague and internally inconsistent. That “Psychosis Risk” was an obvious nonstarter finally got through to the DSM 5 Work Group.

Seemingly, this should have been an end of story moment and we could all breathe a sigh of relief. The obvious and correct next step would be to withdraw the proposal for official recognition and instead relegate Psychosis Risk to where it belongs- in the DSM 5 appendix of suggestions that require further research. Instead, the Work Group is trying to save the suggestion by changing its name and ditching some of its overly ambitious claims.

The idea is to avoid the criticism regarding the high false positive rate by withdrawing claims that the “patients” described are likely to go on to psychosis and that the risk syndrome diagnosis can help to prevent this outcome. But the diagnosis now rests on a new set of equally questionable assumptions, that-1) the people described would have come for treatment anyway; 2) there will be no increase in overall diagnosis, just more accurate diagnosis;
3) inappropriate antipsychotic use can be contained by physician education; and, 4) the new name will carry less stigma.
.
The Work Group has always been well intentioned, but is as dead wrong in its new claims as it was in its old. Were this diagnosis to be made official- however renamed – it would certainly be used (and probably widely misused) to diagnose youngsters who previously would have avoided diagnosis and treatment. Particularly given the imprecise writing of the criteria set, it will mislabel many teenagers- especially those who are using substances, but also those who are creative or eccentric, and/or have difficult relationships with their parents. The experts on the Workgroup might make these mistakes infrequently, but they can’t responsibly make suggestions that are usable only by experts like themselves. Once official, the diagnosis will be misused in ways they never imagined or would accept and will lead to even greater misuse of antipsychotics. And the Work Group can’t rely on the wonders of physician education to clean up the mess they will be making. Most of the physician education will come from the very drug companies that have already shown themselves remarkably adept at furthering the overprescription of antipsychotics to children and teenagers.

Read the rest of the article here: http://www.psychologytoday.com/blog/dsm5-in-distress/201007/psychosis-risk-syndrome-just-risky-new-name

More information on Patrick McGorry and Pre Psychosis Risk Syndrome: http://www.cchrint.org/2010/05/21/meet-the-psychiatrist-pushing-for-a-brave-new-world-of-pre-drugging-kids%E2%80%94patrick-mcgorry/

http://www.cchrint.org/2010/06/16/australian-psychiatrist-patrick-mcgorry-wants-his-pre-drugging-agenda-to-go-global/

http://www.cchrint.org/2010/06/29/pre-crime-try-pre-diagnose-and-pre-drug-psychiatrists-target-infants-as-mental-patients-2/

« Return to news items


Share

Badmouthing Your Ex Could be a Psychiatric Disorder

Friday, July 30th, 2010

StrollerDerby
By Heather Turgeon
July 30, 2010

The diagnosis of Parental Alienation Disorder is being considered for inclusion in the upcoming edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Advocacy groups and clinicians are pushing for it to go through – saying that it’s a real condition that affects a huge number of children.

The clinical picture: a divorced family in which the child is brainwashed by one parent to believe that the other parent is the bad guy (without good reason). In mild form it means withholding or interfering with visits to the other parent, not being able to tolerate being in the same room, or making subtle negative comments that influence the kid’s feelings about his mom or dad.  The severe form?

One of the speakers at an upcoming conference of the Canadian Symposium for Parental Alienation Syndrome, Pamela Richardson, describes her own experience losing her four-year-old son after going through a divorce. Richardson says, in her book A Kidnapped Mind, that her husband emotionally abused their son – teaching him slowly but surely to hate his mother and eventually cut off communication.

Read entire article here:  http://blogs.babble.com/strollerderby/2010/07/30/new-diagnosis-could-impact-family-divorce/

« Return to news items


Share

Pharmaceutical companies deceive public—case in point; Antidepressants

Thursday, July 29th, 2010

The Star Phoenix
By Mark Lemstra
July 29, 2010

We could save $2 billion a year on health-care costs in Saskatchewan while improving health outcomes if we adopt evidence-based protocols.

To do so, we need to find about $40 million of efficiency in each of about 50 areas.

This is the third article in a five-part series on depression. My first column discussed the limitations in diagnosing depression. The second presented literature reviews that concluded antidepressants are no more effective than placebos in treating depression.

This column explains how the drug companies deceive us. Let’s start with some general information and proceed to specific examples for antidepressants.

In 2008, the editor of the New England Journal of Medicine wrote an editorial for the Journal of the American Medical Association, titled: Industry sponsored research: A broken system?

Based on her tenure as the editor of the world’s most prestigious medical journal, Dr. Marcia Angell made some accusations. She wrote that drug companies often design studies, conduct the data analysis, decide which data will be included or suppressed, write the papers, pay for prestigious clinicians to put their name on papers already written by the drug company, and then decide how and when the paper will be published.

Dr. Angell concluded: “Drug companies now finance most clinical research on prescription drugs, and there is mounting evidence that they often skew the research they sponsor to make their drugs look better and safer. Physicians can no longer rely on the medical literature for valid and reliable information.”

She also published a best selling and award-winning novel, The Truth about Drug Companies: How They Deceive Us and What to Do About It.

Let’s look at some examples from anti-depressants.

A research team from the United States, which was skeptical about the benefits of antidepressants, used the Freedom of Information Act to obtain results from the U.S. Food and Drug Administration for all placebo-controlled trials. The team was startled to learn that 40 per cent of the studies had been suppressed because of negative results.

When all the studies were included, incorporating the negative studies, the authors concluded that “antidepressants are little more than active placebos, drugs with very little specific benefit, but with serious side-effects.”

The resulting publication in Prevention and Treatment made headlines around the world. And although regulatory agencies in Europe have begun to respond, there has been no response in North America.

At this point, let’s discuss the potential side-effects of antidepressants in a review from Harvard Medical School, titled: What are the real risks of antidepressants?

The most serious of these includes the increased risk of attempted suicide, especially among children. Other side-effects include insomnia, skin rashes, headaches, joint and muscle pain, stomach upset, nausea, diarrhea, reduced blood clotting capacity, stomach bleeding, uterine bleeding, tics, muscle spasms, trembling limbs, restlessness, severe anxiety, reduced sexual interest, reduced sexual performance, reduced sexual satisfaction, disturbed heart rhythms and reduced liver function.

There are also complications when antidepressants are taken with other drugs, and there is a long list of side-effects when antidepressant use is discontinued, including dizziness, loss of co-ordination, fatigue, burning sensations, blurred vision, insomnia, vivid dreams, nausea, diarrhea, flu-like symptoms, irritability, anxiety and crying spells.

Recently, the antidepressant Serzone was removed from the market after it was associated with hepatitis and liver failure.

The most worrisome side-effect is the increased risk of suicide attempt so let’s take a closer look.

Another review from the Food and Drug Administration found that not only do antidepressants provide no benefit to children, but the drugs are associated with a 50 per cent increase in suicidal behaviour.

Regrettably, these negative results, too, were buried by the drug companies.

Read the rest of this article here:  http://www.thestarphoenix.com/news/Pharmaceutical+companies+deceive+public/3336124/story.html

Previous articles in this series: Effect of antidepressants, placebos similar by Mark Lemstra
http://www.thestarphoenix.com/health/Effect+antidepressants+placebos+similar/3307896/story.html

Expanding mental disorders list adds to cost by Mark Lemstra
http://www.thestarphoenix.com/health/Expanding+mental+disorders+list+adds+cost/3280676/story.html

« Return to news items


Share

The Guardian: Mental Health Diagnoses Mask the Real Problems—Range of new diagnoses is mythology, not scientific text

Thursday, July 29th, 2010

The Guardian
By Dorothy Rowe
July 29, 2010

A textbook of mental health disorders makes it far too easy for doctors to label patients – and disregard the roots of suffering

The Diagnostic and Statistical Manual, whose updated fifth edition will include a range of new diagnoses, is a mythology, not a scientific text. It is created by American psychiatrists who meet in groups to consider whether or not a certain diagnosis should be included in the DSM. These groups meet a number of times so that they can say that their agreement about a certain diagnosis is reliable. Thus they could reliably agree that there is a mental disorder called Guardian Readers’ Personality Disorder with the symptoms of a need to read this paper regularly, an overvaluation of the Guardian, and so on. Who knows, it might already be in the most recent version of the DSM.

In their book, Making Us Crazy: DSM – The Psychiatric Bible and the Creation of Mental Disorders – which won the Mind Book of the Year Award in 1999 – Herb Kutchins and Stuart A Kirk wrote: “DSM is a book of tentatively assembled agreements. Agreements don’t always make sense, nor do they always reflect reality. You can have agreements among experts without validity. Even if you could find four people who agreed that the earth is flat, that the moon is made of green cheese, that smoking cigarettes poses no health risks, or that politicians are never corrupt, such agreements do not establish truth.”

For any statement to be valid there has to be evidence for that statement outside of the statement itself. Thus any textbook of physical disorders will list not just the symptoms of each illness but evidence that exists separate from those symptoms and that is derived from a wide variety of tests. Apart from the disorders listed in the DSM as the result of brain trauma, there are no physical tests for any of the disorders listed in the DSM. No physical cause has been found for any of these mental disorders. The diagnosis you receive from a psychiatrist is no more than the psychiatrist’s opinion of what you have told him. Go to another psychiatrist and you’re likely to get a different diagnosis.

Why do psychiatrists accept such an unscientific document as the DSM? In her book, The Users and Abusers of Psychiatry, my colleague Lucy Johnstone wrote, “To admit the central role of value judgments and cultural norms [in the creation of the DSM] is to give the whole game away. The DSM has to be seen as reliable and valid, or the whole enterprise of medial psychiatry collapses.”

Legal cases and medical insurance require any doctor or psychologist filling in the necessary forms to state a diagnosis. In the UK many psychiatrists, GPs and psychologists now see applying a DSM diagnosis to a patient as a pointless exercise, but feel that it is not in their patient’s interest to refuse to fill in this part of the form. However, there are still far too many doctors and psychologists who are too intellectually lazy to think about patients as individuals, or too fond of the many freebies that the drug companies provide for them. These are the ones who spring to the defence of the DSM.

Read entire article here:  http://www.guardian.co.uk/commentisfree/2010/jul/29/mental-health-diagnostic-manual

« Return to news items


Share

CBS Health News: Will New Psych “Bible” Make Everyone Crazy?

Thursday, July 29th, 2010

CBS News
By David W. Freeman
July 29, 2010

Is anyone normal anymore?

An updated edition of the medical reference doctors use to diagnose mental illnesses could include a range of brand-new disorders, including some that describe thought patterns and behaviors that have long been considered mere quirks or examples of eccentric behavior.

Like what?

Are you angry at something or do you have “temper dysregulation disorder?”

Feeling upset or do you have “mild anxiety depression?”

And then there’s “psychosis risk syndrome,” a diagnosis that could apply to people who seem merely to be at increased risk for full-blown psychosis,.

The new edition of the book – the “Diagnostic and Statistical Manual,” or “DSM” – is considered the bible of mental illness. It contains specific criteria for diagnosing mental illness and is used around the world.

The new edition of the DSM isn’t due out till 2013. But medical experts met on Tuesday to discuss changes being considered to the text, Reuters reports.

Will the revised DSM help people get treatment for psychological problems that now go undiagnosed and treated? Or will it understate the impact of mental illness by suggesting that the term applies to a much wider swath of the population?

Some doctors worry that with so many new disorders, few people will be classified as mentally healthy.

Read entire article here:  http://www.cbsnews.com/8301-504763_162-20012048-10391704.html

« Return to news items


Share

Biological Psychiatry—Following the Money

Wednesday, July 28th, 2010

The New American
By Beverly Eakman
July 28, 2010

Despite the public relations campaign aimed at “de-stigmatizing mental illness,” scores of permanent, stereotyping labels are assigned to what are basically annoying habits: clicking a pen repeatedly (anxiety), talking fast (hysteria), repeating a favorite song over and over (obsessive-compulsive disorder), wiggling in a chair (hyperactive). Even crazes like text-messaging are not immune from diagnosis. Attitudes that may be in bad taste or out-of-fashion, but certainly not “dangerous” or “wrong,” are also viewed with suspicion and sometimes criminalized.

Another sleight-of-hand explains why the public doesn’t come down harder on legislators, schools and other agencies that play hardball with their mental-health extremism. It’s called the private-public partnership. This has become a way to muddy the waters so that parents and other taxpayers have to spend weeks or months figuring out exactly who paid for what. For example, the UNC’s schizophrenia study was paid for by researchers from Columbia University, which merely “contributed” to it. Federally funded grants form the National Institute of Mental Health paid the lion’s share, with a large influx from the privately funded Foundation of Hope — a public-private partnership in and of itself that supports mental-health causes.

The Foundation’s website gives a fairly representative look at how the public-private process works: “The Foundation of Hope has given over $2 million to fund local [mental health] research projects and treatment programs. This ‘seed money’ has leveraged an additional $89 million in federal grants at The University of North Carolina at Chapel Hill and Dorothea Dix Hospitals.” [Emphasis added]

Thus, it is seed money from established, private entities that helps spread legitimacy. That legitimacy leads the federal government and other well-endowed groups (charities, universities, and even political think tanks) to commit resources to the same cause and in the end institutionalizes it.

This round-about method of securing funds is not peculiar to the United States, nor is it limited to causes like mental illness. Candidates for public office, professional agitators for or against certain hot-button issues, and even some government agencies seeking to garner support for oddball legislation use the same game, which is not in the least affected by laws that purport to limit how much individuals or groups can give to a cause or candidate. Small, unorganized bands of “concerned citizens” who don’t know the ropes are often left to locate the money trails — only to discover they have too few resources with which to challenge entities that can afford hire scores of attorneys.

Another financial bonanza lies within the legislative process itself. Example: For every child diagnosed with an ongoing physical or mental illness, a school district – or even individual families — become eligible for various government greenbacks — Medicaid, Special Education and Supplemental Security Income (SSI), for instance.

Let’s take SSI, for example. SSI is yet another program aimed at low-income parents with a child categorized as having a “disability.” These include classifications for mental illnesses found in that official bible of the psychiatric profession, the DSM. The school will get Medicaid or additional Special Education funds. So, there is every incentive for parents — and school districts — to get as many kids as possible diagnosed.

As always, there’s a catch: If a child is referred to a psychiatrist, it is rare for the youngster to walk out without a treatment entailing psychotherapy and/or psychiatric drugs. If a parent later has second thoughts and suspends drug treatment or psychotherapy, he or she can be cited for “medical neglect,” which carries significant penalties, including the child’s removal from the home. Thus any parent who seeks to profit from SSI benefits may regret it.

Intimidation of whistleblowers and dissenting experts are a problem as well. One such professional recently wrote to Dr. Fred A. Baughman, the retired pediatric neurologist cited in Parts I and II of this series, to complain that his refusal to go along with the “chemical imbalances of the brain” theory was rebuffed with the prospect of a suspended license.

Dr. Baughman responded to the gentleman by citing a response he himself had received in 2002 to a letter on that very topic from Bernard Alpert, M.D., President of the Medical Board of California (MBC):  “As you outline in your letter,” wrote Dr. Alpert, “there is tremendous professional support for categorizing emotional and psychological conditions as diseases of the brain.  In published materials, some quoted in your letter, you will find that support from chairs of psychiatry departments, the American Psychiatric Association and professors of major medical schools.  It is clear that the psychiatric community has set their standard, and while one might disagree with it, that standard becomes the legal standard upon which the Board (CMB) must base its actions.”

Citing Dr. Alpert’s response, Dr. Baughman had this to say to his beleaguered colleague:

Unbelievably, what Alpert, speaking for the Medical Board of the State of California, appears to be saying here is that whatever the majority do, including … knowing[ly] violating a patient’s right to informed consent, that that becomes the unassailable, legal ‘standard of practice’. This puts any physician who purveys the truth [as determined through the scientific method], in legal jeopardy….

Separately, antipsychotics have been implicated in a number of deaths, particularly in veterans. The story got little play, but in what coverage it did get, Lt. General Eric B. Schoomaker described “a series, a sequence of deaths” in the “warrior transition units.” In a press release, Dr. Fred A. Baughman said the deaths were “not suicides or ‘overdoses,’ but sudden cardiac deaths due to prescription antipsychotics and antidepressants.” Again, the story got little attention while parents buried their sons and daughters who didn’t have to die.

Read the rest of this article here: http://www.thenewamerican.com/index.php/usnews/health-care/4161-biological-psychiatry-following-the-money

« Return to news items


Share

Science Mag—This Is Your Brain Off Drugs:Why Pharma May Be Cooling on Psychiatry Drugs—no pathology for mental ‘disease’

Wednesday, July 28th, 2010

Though this article includes some scientific/medical terminology, the  significance of what the neurologist is describing is extremely relevant:  Unlike regular “diseases” there is no clear pathology for psychiatric disorders.   See this previous blog/news entry by CCHR on this same subject: Wake Up FDA—Even Drug Giants Are Admitting No Lab Tests Exist To Prove If Antidepressants Work  http://www.cchrint.org/2010/02/05/wake-up-fda%E2%80%94even-drug-giants-are-admitting-no-lab-tests-exist-to-prove-if-antidepressants-work/

ScienceMag.com

by Greg Miller, July 28, 2010

Earlier this year, pharmaceutical giant AstraZeneca announced it was ceasing drug-discovery research for psychiatric disorders such as depression and schizophrenia. The move, along with cutbacks at other companies, has raised concerns about where the next generation of neuropsychiatric drugs will come from—see this Friday’s issue of Science for a feature article exploring this topic.

Yesterday, ScienceInsider spoke with neuroscientist Menelas Pangalos, who in May took over as AstraZeneca’s head of drug-discovery research and early development. His comments have been edited for brevity.

Q: What do the recent changes mean for neuroscience research at AstraZeneca?

M.P.: Basically, from a research perspective, we’re pulling out of the psychiatry space. We’re still very much focused on neurology, so Alzheimer’s disease, pain, cognition, … those areas are still very active.

Q: What makes research on psychiatric drugs less attractive?

M.P.: Our understanding of disease pathophysiology is still relatively in its infancy.

These are complex and heterogeneous disorders. Also, the size and robustness of the clinical trials made it a less attractive area for us to be in compared to other areas we were working in. There has to be a much better alignment between preclinical and clinical work.

Q: How so?

M.P.: In neurology, if you take stroke as an example, preclinical models of stroke tend to be occlusion of the middle cerebral artery, which causes ischemic damage in the brain of a rodent or nonhuman primate that mirrors fairly well what happens in the human situation.

When you start getting into psychiatry, we have tail suspension assays, we have forced swim assays, we have learned helplessness assays … none of which have been developed through a detailed understanding of the pathophysiology. [In these tests, researchers measure how long it takes a rodent to stop struggling after being suspended by its tail or placed in a pool of liquid; giving up is presumed to be a rodent version of despair.]

Read the entire article here:  http://news.sciencemag.org/scienceinsider/2010/07/this-is-your-brain-off-drugs-why.html


« Return to news items


Share

The BBC—new report challenges psychiatry’s billing bible, the DSM—”Mental Health: Are we all sick now?”

Wednesday, July 28th, 2010

BBC News
By Philippa Roxby
July 28, 2010

Diagnosing psychiatric illness has always been controversial, mental health experts say. Now some are worried that a new draft of the diagnostic ‘bible’ for mental health medicine could result in almost everyone being diagnosed with a mental condition.

The diagnostic ‘bible’ in question is the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association.

The US manual is used worldwide as a basis for diagnosis, research and medical education.

Its forthcoming fifth edition – known in the profession as as DSM-5 – is set to contain a range of new diagnoses, including conditions such as “mixed anxiety depression, psychosis risk syndrome and temper dysregulation disorder”, as well as the more mundane binge eating.

The danger, say experts writing in a special issue of the Journal of Mental Health, is that there has not been enough research to back up these changes.

Even the smallest shift in how to define something like depression could have huge implications.

Self-fulfilling

Dr Felicity Callard, senior research fellow at the Institute of Psychiatry, King’s College London, says it is crucial to understand what happens when people are over-diagnosed.

“There are very big potential implications on how people, particularly adolescents, respond to being told they have a mental illness. It’s likely there will be harmful consequences,” she said.

She cites the “at risk psychosis syndrome” diagnosis as an example of a label which is given to young people who ‘might’ have psychosis – characterised by abrupt changes in personality. It is a diagnosis of something which could result in a disorder, but only potentially. That can have complicated effects, she says.

“Imagine a young person being told that they are “at risk” of developing a mental illness. How would that affect that individual’s behaviour? Could it lead to increased stigma or even discrimination? And how might it affect the parents and family of that person too?”

Jerome Wakefield of New York University’s Department of Psychiatry writes: “One of the most frightening scenarios is the potential for medicating people – particularly children – who haven’t yet shown any signs of illness in a bid to ‘treat’ them.”

These concerns are shared by a number of clinical experts in the Journal of Mental Health.

Read entire article here:  http://www.bbc.co.uk/news/health-10787342

« Return to news items


Share

British psychiatrists warn APA’s new “mental disorders” will turn large numbers of normal people into psychiatric patients

Tuesday, July 27th, 2010

The Press Association
July 27, 2010

A further step in the Americanisation of mental healthcare threatens to turn large numbers of “normal” people into psychiatric patients, British experts warned.

Sweeping changes to a diagnostic “bible” that influences practitioners around the world could make it far easier to be labelled with a psychological problem, it is claimed.

One suggestion of the US authors is a new diagnosis of “psychosis risk syndrome” which singles out people thought to be at risk of developing a psychotic illness such as schizophrenia.

Individuals falling into this category might experience occasional mood changes, feelings of distress, anxiety or paranoia, or fleeting episodes of hearing voices.

In the past they might have been considered difficult or eccentric. Under the new proposals they could receive a diagnosis that affects their future lives and job prospects. Yet they may never develop “full blown” psychosis.

Other diagnoses under consideration include “mixed anxiety depression”, “binge eating, and “temper dysregulation disorder with dysphoria”. In addition, the bar could be lowered on some common existing disorders, such as depression, so that more people are considered to have symptoms that warrant a diagnosis.

Professor Til Wykes, from the Institute of Psychiatry at King’s College London, spoke of a trend that was “leaking into normality”. She said: “It shrinks the pool of normality to a puddle, and there are going to be fewer people who won’t end up having a diagnosis of mental illness.”

Prof Wykes edits the Journal of Mental Health which carries a “health warning” about the proposals in its latest issue. The changes have been put forward for discussion by a powerful group of US experts working on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Read entire article here:  http://www.google.com/hostednews/ukpress/article/ALeqM5gHnD0Z3xJQt8sJ8PEIComLTtomvg

« Return to news items


Share